Skip to Main Content

Paper Details

Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial.
Nat Commun
17
2023
Author NameAffiliation
Thomas JohnOlivia Newton-John Cancer Research Institute
Frances A ShepherdPrincess Margaret Cancer Centre, and the University of Toronto
J. Carl BarrettOncology R&D
  • 1 - 3

Datasets

Release 1.2